Aims and Objectives: To compare the efficacy, safety, and rate of response of intravenous iron sucrose and intramuscular iron Sorbitol therapy for anemia during pregnancy. Material and Methods: 100 antenatal cases of gestational age 16-32 weeks were included in this prospective study. Cases were randomly divided into two groups. Group A, having 50 cases received intravenous iron sucrose, and 50cases in group B received intramuscular iron sorbitol. Response to therapy in both groups was studied and compared. Results: The mean pretherapy hemoglobin in group A was 6.49 g/dl and in group B was 6.48 g/dl. The rise in hemoglobin after 4 weeks of starting therapy was 3.52 g/dl in group A and 2.33 g/dl in group B The difference was Statistically significant (P<0.01) The mean time taken to achieve target hemoglobin (>11 g/dl) was 6.37 weeks in group A and 9.04 weeks in group B. In group A, 8% (four) cases had grade I adverse effects. In group B, 24% (12) cases had grade I adverse effects. The difference was statistically significant (P=0.027). In both the groups no case discontinued the therapy. Conclusion: Intravenous iron sucrose is safe, convenient, more effective, and faster acting therapy than intramuscular iron sorbitol therapy for treating moderate to severe anemia during pregnancy.
Select your language of interest to view the total content in your interested language